Summary of the EMA September 2022 Qualification Opinion for PROCOVA™

On September 15, 2022, the European Medicine Agency (EMA) qualified Unlearn’s patent-pending procedure to leverage historical data and machine learning to reduce sample sizes or increase power in pivotal trials using patient-specific prognostic scores without creating bias. The adopted qualification opinion focuses on our 3-step PROCOVA™ procedure, which provides the regulatory framework for planning and conducting a Phase 2 or Phase 3 TwinRCT™, the novel randomized trial enhanced with Prognostic Digital Twins.

The adopted qualification opinion was published including links to a handbook for the target trial statistician and two other documents that were part of the review process with Committee for Medicinal Products for Human Use (CHMP). The four documents collectively are 62 pages long. Thus, the purpose of this document is to (1) direct the reader to the most important sections of the qualification opinion, (2) to give a brief overview of the critical elements of the PROCOVA procedure, and (3) to address FAQs about the opinion and the supporting documents.

The draft qualification opinion, published in March of 2022, can be found here.

Enter your email address to download paper.

Click the link to begin download.
Oops! Something went wrong while submitting the form.

Enter your email address to watch the webinar.

Click the link to watch webinar.
Oops! Something went wrong while submitting the form.
Webinars

How will AI transform the future of medicine?

White Papers

Evaluating Digital Twins for Alzheimer’s Disease using Data from a Completed Phase 2 Clinical Trial

White Papers

Prognostic digital twins overcome the limitations of external control arms in RCTs

Both methods reduce control arm sizes, but only digital twins control for bias.
A Phase 2 study on crenezumab in mild-to-moderate AD was used to retrospectively assess the validity of Unlearn's approach for AD clinical trials.
Hear from Charles Fisher, founder and CEO of Unlearn, in this on-demand webinar about how AI will transform the medical landscape of tomorrow.